Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARANA
2014-000476-26Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Netherlands Cancer Institute. Primary endpoints: Androgen receptor chromatin binding patterns and downstream responsive genes and PSA and KI-67 changes. Started Feb 2015; status: active.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2014-000476-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000476-26.